Diseases Treated by Blood and Bone Marrow Transplantation
The American Family Children’s Hospital has a Foundation for the Accreditation of Cellular Therapies-accredited, state-of-the-art bone marrow transplant unit complete with spacious patient rooms and lounge areas situated within a HEPA-filtered environment.
Patients undergo transplant for a wide variety of malignant and non-malignant conditions including:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Hodgkin’s Lymphoma
- Non-Hodgkin’s Lymphoma
Bone Marrow Failure Syndromes
- Aplastic anemia
- Fanconi Anemia
Primary Immune Deficiencies
- Severe combined immunodeficiency syndrome (SCID)
- Wiskott-Aldrich syndrome
- Chronic Granulomatous Disease
- Hemophagocytic Lymphohistiocytosis
- Langerhans Cell Histiocytosis
We are able to offer a wide variety of transplant options using all stem cell sources (e.g. bone marrow, peripheral blood stem cells and umbilical cord blood) including:
- HLA matched sibling
- Adult Unrelated donor
- Umbilical Cord Blood units
- Haploidentical (parent to child)
Our transplant team consists of four physicians, a nurse practitioner and representatives from many other disciplines, including nutrition, child psychology, child life, social work, pharmacy and rehabilitative services. We are a designated Children’s Oncology Group transplant center and members of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), the National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
In addition, we have established novel laboratory and clinical research programs focused on the use of post-transplant immunotherapy to treat cancer. We are one of 27 member centers of the Cancer Immunotherapy Trials Network (CITN) in the US, and have research labs within the Hematology, Oncology & BMT division dedicated toward developing novel immunotherapies for cancer. We are also one of very few centers that offer I-131 MIBG therapy to treat patients with relapsed or refractory neuroblastoma.
In addition, through a novel institutional phase I clinical trial, we offer Natural Killer (NK) cell infusions to children with refractory cancer after haploidentical stem cell transplant. Our Production Assistance for Cellular Therapies (PACT) center serves as a resource for optimizing novel cell therapies, such as natural killer cell infusions, for children with refractory cancer, and UW is one of only five PACT centers nationwide designated by the National Heart, Lung and Blood Institute.
Wisconsin is one of a small number of states that currently screens for Severe Combined Immune Deficiency and other T cell lymphopenias in the Newborn Screening Program. This allows early identification and referral to tertiary care centers of infants born with this fatal disease. Early transplantation can be life-saving in these infants, especially if performed prior to the development of life-threatening infections. Our division works very closely with Pediatric Immunologists to identify and appropriately treat newly diagnosed infants.
Meet our Transplant Physicians
Kenneth DeSantes, MD (Director, Pediatric Bone Marrow Transplant Program)
Pediatric Bone Marrow Transplant Research Programs